Previous Article |
Table of Contents
| Next Article
a Laboratory of Immunopathology, National Institute of
Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD 20892-0760; b Surgical Neurology Branch,
National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, MD 20892; c Department of
Biological Sciences, University of Essex, Wivenhoe Park, Colchester CQ4
3SQ, United Kingdom; Departments of d Genetics and Pathology
and e Development and Genetics, Uppsala University,
Norbyvägen 18A, S-752 36 Uppsala, Sweden; f Department
of Psychiatry and Behavioral Science, State University of New York,
Stony Brook, NY 11794-8101; g Institute of Genetic Medicine,
Johns Hopkins University School of Medicine, Ross 1064, 720 Rutland
Avenue, Baltimore, MD 21205; h Gene Therapy Research Unit,
Centenary Institute and Sydney Cancer Centre, Newtown NSW 2042, Australia; i Department of Chemistry and Biochemistry and
the School of Medicine, University of South Carolina, Columbia, SC
29208; and k Genetisches Institut der
Justus-Liebig-Universität, Heinrich-Buff-Ring 58-62, 35392 Giessen, Germany
Communicated by George Klein, Karolinska Institute, Stockholm,
Sweden, March 4, 2002 (received for review February 6, 2002)
CTCF, a conserved, ubiquitous, and highly versatile
11-zinc-finger factor involved in various aspects of gene regulation, forms methylation-sensitive insulators that regulate X chromosome inactivation and expression of imprinted genes. We document here the existence of a paralogous gene with the same exons encoding the
11-zinc-finger domain as mammalian CTCF genes and thus
the same DNA-binding potential, but with distinct amino and carboxy termini. We named this gene BORIS for
Brother of the Regulator of Imprinted Sites. BORIS is present only
in the testis, and expressed in a mutually exclusive manner with CTCF
during male germ cell development. We show here that erasure of
methylation marks during male germ-line development is associated with
dramatic up-regulation of BORIS and down-regulation of
CTCF expression. Because BORIS bears the same
DNA-binding domain that CTCF employs for recognition of methylation
marks in soma, BORIS is a candidate protein for the elusive epigenetic
reprogramming factor acting in the male germ line.
The ubiquitous, highly
conserved, multivalent 11-zinc-finger (ZF) factor CTCF plays multiple
roles in gene regulation, depending on the combinatorial utilization of
different ZFs to bind varying CTCF target sites (1). CTCF-DNA complex
formation can be regulated by CpG-specific DNA methylation (2, 3) if
the involved CpG nucleotides are present within 50-60-bp-long CTCF
target sequences precisely at DNA base positions required for
recognition by the ZFs (2). Among the multitude of normal CTCF
functions (1), its involvement in partitioning the genome into active
or inactive domains by means of a chromatin insulator function (4) has received particular attention. This feature creates functionally autonomous gene cluster/expression domains by preventing unscheduled activation or silencing by neighboring regulatory elements. For example, the methylation-sensitive chromatin insulator within the
imprinting control region (ICR) between IGF2 and
H19 genes (5) regulates its interaction with CTCF in
vivo (2), which likely results in maternal-specific repression of
the IGF2 gene.
Strikingly, all vertebrate chromatin insulators identified so far
interact with CTCF (1, 3, 6). Moreover, sites with proven or proposed
potential to interact with CTCF include other epigenetic centers, such
as the ICR within the Prader-Willi/Angelman syndrome
locusm conserved regions within reciprocally
imprinted Dlk1/Gtl2 genes (7, 8) and
the Kcnq1 ICR (ref. 9; and G. Fitzpatrick, E.P., C.K., R.O.,
M. Higgins, and V.V.L., unpublished data). Finally, the
choice/imprinting center of the XIST antisense gene,
Tsix, contains several tandem CTCF-binding sites, which
collectively function as CTCF-driven chromatin insulators (10).
Although the mechanism for reading of at least some imprinting
marks in somatic cells may be explained by allele-specific interactions
between CTCF and ICRs, there is as yet no explanation for the targeting
mechanism by which the differentially methylated states of the
CTCF-dependent ICRs are established de novo. By screening
testes nuclear extracts for proteins binding to CTCF target sites, we
identified and cloned a previously uncharacterized factor that shares
all 11 ZFs with CTCF while being different in the regions flanking this
DNA-binding domain. This CTCF-paralogue gene, termed
Brother Of the Regulator of
Imprinted Sites, or BORIS, may provide
a conceptual framework for understanding epigenetic reprogramming
events that go beyond the imprinting phenomenon.
Nuclear Extracts (NE) and Electrophoretic Mobility Shift Assays
(EMSA).
NE from tissues were prepared as described (11), and used in
EMSA with DNA probes and antibodies as described (2, 12, 13).
PCR-Mediated Screening for CTCF-Like cDNA Sequences and
Isolation of Human and Mouse BORIS cDNAs.
PCR-screening primers are listed in Supporting Text,
which is published as supporting information on the PNAS web site,
www.pnas.org. Following cloning and sequencing of PCR products obtained
using the Marathon-Ready human testis cDNA (CLONTECH), one such
fragment displayed a human cDNA sequence containing an ORF encoding
CTCF-like ZFs. This was used to design the specific pairs of primers
for PCR analyses of the Rapid Screen Arrayed human testis cDNA Library Panel (OriGene Technologies, Rockville, MD), as well as for the 5' and 3' rapid amplification of cDNA ends (RACE) with the
Marathon-Ready testis cDNA and adaptor primers from the Marathon cDNA
Amplification kit (CLONTECH). 5' RACE was performed using the GeneRacer
kit (Invitrogen). The mouse BORIS homologue was
similarly amplified using the Marathon-Ready mouse testes cDNA library (CLONTECH).
RNA Isolation, Northern Blots, and Reverse Transcription (RT)-PCR.
Northern blots of isolated RNA (14) were probed with the
NdeI-AccI fragment of the 5' end of human
CTCF cDNA clone p7.1 (14) and the
XhoI-XhoI fragment of the BORIS cDNA
(Fig. 2A). Expression patterns were determined by
RT-PCR using human BORIS-specific primers (forward,
5'-caggccctacaagtgtaacgactgcaa-3'; reverse, 5'-gcattcgtaaggcttctcacctgagtg-3') in parallel with amplification of
human Expression of CTCF and BORIS in Pichia pastoris.
CTCF was purified as originally described (15) with modifications
outlined recently (12). Expression of BORIS in yeast was accomplished
using the Pichia Expression Kit (Invitrogen) according to the
manufacturer's instructions, with chromatography steps similar to
those described for CTCF (12).
Antibodies (Ab).
Rabbit antiserum against the bacterially produced N-terminal
domain of CTCF (16) was produced as previously described for Ab against
synthetic CTCF peptides (17). Chicken Ab against synthetic BORIS
peptides (Fig. 2B) were produced by Aves Labs (Tigard, OR), purified, and characterized as described in Fig. 6, which is published as supporting information on the PNAS web site.
In Situ Analyses of mRNA, Protein, and
Cytosine-Methylation.
Digoxygenin-11-dUTP or biotin-16-dUTP-labeled (Boehringer) 5' end
of the BORIS cDNA were hybridized to formaldehyde-fixed or frozen sections of mouse and human testis as described (18). For immunostaining, the slides were boiled for 10 min in 1×
Citra (InnoGenex, San Ramon, CA), followed by
incubation with affinity-purified chicken anti-BORIS, rabbit anti-CTCF,
or sheep anti-5-methylcytosine (anti-5mC) Ab (Maine Biotechnology
Services). The BORIS and CTCF epitopes were visualized by
FITC-conjugated rabbit anti-chicken (Dako) and alkaline phosphatase
(AP)-conjugated (using the 5-bromo-4-chloro-3-indolyl-phosphate substrate; Roche) goat anti-chicken or goat anti-rabbit (Promega) secondary Ab. For double-staining of chicken anti-BORIS and sheep anti-5mC Ab, a goat anti-chicken secondary Ab conjugated to biotin (Vector), with subsequent detection by avidin-Rhodamine (Vector), was
used for BORIS detection, and rabbit anti-sheep Ab conjugated to FITC
(Vector) for detection of 5mC.
Detection of a CTCF-Like DNA-Binding Protein in Testes NE.
Using EMSA analyses of several well characterized
CTCF-target sequences (1), we could document that testis NE produced a
DNA-protein complex with a mobility slightly slower than that for the
CTCF complex (Fig. 1A). This
activity was not detected in NEs from a variety of somatic tissues from
rats and mice (Fig. 1; data not shown). The binding activity in testis
NEs could be competed with an excess of unlabeled DNA fragments bearing
other CTCF targets, but not with the same fragments mutagenized at
specific CTCF-contacting bases described previously (2, 3, 14, 17, 19).
Fig. 1A also shows that the testis-specific factor could be "supershifted" in EMSAs with an excess of anti-CTCF-C Ab
against the C-terminal region of CTCF downstream from the middle of the
11-th ZF. However, in contrast to DNA-bound CTCF, this testis-specific
activity could not be supershifted by Ab against the N-terminal region
upstream of the first ZF. These results suggested that in addition to
CTCF, testis NE contained a different form of CTCF or a protein highly
related to CTCF.
Developmental Biology
BORIS, a novel male germ-line-specific protein associated with
epigenetic reprogramming events, shares the same 11-zinc-finger domain
with CTCF, the insulator protein involved in reading imprinting
marks in the soma
![]()
Abstract
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
![]()
Introduction
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
![]()
Material and Methods
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
-actin (primers from OriGene) as an internal control. Mouse
BORIS-specific primers (forward,
5'-gagagacagacaagagagaagagaggttgctc-3'; reverse,
5'-cctgtgtgggtgttcacatggttcctaagaag-3') were used together with the
primers for mouse
-actin. For detection of CTCF mRNA, primers E5E6up
(5'-tcgcaagtggacacccaaatc-3') and E4E5down
(5'-gaacccattcaggggaaaagc-3') were used. For both CTCF and
BORIS, the primers used for RT-PCR were chosen so as not to
amplify genomic DNA.
![]()
Results
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References

View larger version (78K):
[in a new window]
Fig. 1.
EMSA analyses. (A) EMSA analyses of nuclear
extracts (NEs) from rat liver versus testis tissues. no Ab, marked by
downwards brackets, no antibodies were added to the EMSA reactions;
anti CTCF-C Ab and anti CTCF-N, reactions contained affinity-purified
antibodies against either the C-terminal CTCF region or the N-terminal
CTCF region, respectively; Control Ab, equal amounts of the rabbit
irrelevant polyclonal IgGs (in this case against GATA-1 protein). FL
BORIS and FL CTCF, EMSA results with the full-length BORIS and CTCF
proteins. Positions of protein-free FII DNA probe (F), and of the
protein
CTCF- or BORIS-bound probe
are indicated by the arrowheads.
(B) "Supershifting" EMSA with three
anti-BORIS-peptide chicken antibodies and two anti-CTCF antibodies
(marked at the top of the gel) and recombinant full-length (FL) CTCF
and FL BORIS proteins produced in Pichia pastoris.
Cloning of Human cDNA Encoding BORIS.
Conserved regions within the vertebrate CTCF
cDNAs were used to design a variety of primers for PCR amplification of
CTCF-like sequence fragments from a human testis cDNA
library that were then cloned and sequenced. Of more than 100 fragments, one PCR product contained a CTCF-like sequence
encoding an amino acid sequence practically identical to that of
ZF 4, 5, and 6 of CTCF. After additional PCR-mediated screening and 5'
rapid amplification of cDNA ends (RACE), we identified an
4-kb-long
cDNA encoding a previously uncharacterized protein with all 11 CTCF-like ZFs (see Fig. 6). An alignment with CTCF sequence
(Fig. 2A) revealed a remarkable similarity between
the two 11-ZF domains, including most of the major DNA-base-recognition
residues at positions
1, 2, 3, and 6 (1, 3) within each ZF. Referring
to the CTCF function in reading imprinting marks in soma, we termed
this previously unknown protein BORIS.
|
To verify that the cloned BORIS cDNA encodes the same CTCF-site-binding activity, and the same pattern of recognition by anti-CTCF Ab, as initially detected in testis NE by EMSA, the clone was used as a template for coupled in vitro transcription/translation and to produce a full-length recombinant BORIS in Pichia (12, 15). EMSA of the resulting full-length BORIS proteins demonstrated that recombinant BORIS forms a complex with the FII DNA, generating the same-mobility EMSA band as that produced by the endogenous BORIS from testis (Fig. 1A). Conversely, recombinant full-length CTCF produced the faster-migrating band present in NE from a variety of tissues (Fig. 1A; data not shown). DNA-bound recombinant BORIS interacted with an excess of anti-CTCF-C Ab, but not with anti-N-CTCF Ab (Fig. 1B Left), whereas DNA-bound recombinant CTCF was recognized by both of these Ab (Fig. 1B Right). The C-terminal regions of both proteins display two motifs of sufficient homology (shown underlined as shared epitope-CTCF-C in Fig. 2A), explaining the cross-reactivity of anti-CTCF-C Ab with BORIS. Fig. 1B also demonstrates that each of the three anti-BORIS chicken Ab, but not a control Ab, interacted specifically with DNA-bound recombinant BORIS, but not CTCF. These results prove that BORIS encoded by the human cDNA that we cloned corresponds to the endogenous testis-specific CTCF-target-binding activity, and that BORIS proteins are conserved in humans and rodents.
BORIS Is a Paralogue of CTCF.
We cloned the mouse BORIS counterpart with the entire ORF followed by the 3'-UTR with the poly(A)-tail (see Fig. 7, which is published as supporting information on the PNAS web site). The Bestfit alignment of mouse and human BORIS amino acid sequences (Fig. 2B) shows that, although all 11 ZFs are practically identical, the regions outside the ZFs are overall only similar but do contain several highly conserved motifs. Although CTCF is overall 93% conserved in avian and mammalian species (1), the regions of mouse and human BORIS and CTCF proteins outside of the "shared" 11 ZFs display no similarity to each other or to other known protein signature motifs.
A comparison of the overall genomic organization (Fig. 2C) and of the intron-exon junction sequences (see Table 1, which is published as supporting information on the PNAS web site) of avian (20), mouse, and human CTCF (13) with that of BORIS revealed striking similarities between BORIS and mammalian but not avian CTCF. This finding suggests that the CTCF and BORIS ZF exons have descended with divergence from a common ancestral gene. The idea that BORIS evolved through duplication and transposition events during mammalian radiation is further supported by our analyses of chromosome localizations of the two genes. A DNA fluorescence in situ hybridization (FISH) probe containing human BORIS exons revealed a single spot on chromosome segment 20q13.2 without any crosshybridization to other chromosomes (data not shown). This agrees perfectly with the Human Genome mapping data (http://genome.ucsc.edu/goldenPath/hgTracks.html), which placed contigs with BORIS exons (AL160176-AL035541) to the distal half of the chromosomal band 20q13.2. The conclusion that BORIS is a paralogue of CTCF is also supported by a "human genome paralogy" map (21) that relates a region flanking the BORIS-containing locus at 20q13 to the CTCF-containing region of chromosome 16q22 (ref. 30; http://u119.marseille.inserm.fr/Db/paralogy.html). A duplication event involving a larger chromosome region harboring several genes in addition to CTCF was likely to have occurred first, followed by further divergence of the initially duplicated region to yield BORIS with a testis-specific promoter (see below).
BORIS Expression Is Testis-Specific and Confined to CTCF-Negative Male Germ Cells Undergoing Genome Remethylation.
The pattern of BORIS expression was analyzed by
Northern blots with poly(A)+RNA (Fig.
3A) and by RT-PCR with cDNAs
from 24 human and 24 mouse tissues (Fig. 3 C and
D). Internal controls were
-actin (Fig. 3 C
Upper and D Upper) and CTCF (Fig.
3B; data not shown). These studies showed that expression of
BORIS transcripts was testis-specific in both species and
that even with the high sensitivity of RT-PCR, BORIS
expression was below the limits of detection in mouse or human ovaries,
and in tissues of 8.5-day to 19-day mouse embryos.
|
To identify BORIS-positive cells in testis, affinity-purified chicken Ab "ap-2-Ab" against the peptide 2, which contains a motif conserved in the mouse and human proteins (Fig. 2C), was generated. Western blot analyses showed that the ap-2-Ab bound specifically to the endogenous BORIS polypeptide in testis NE (see Fig. 8, which is published as supporting information on the PNAS web site). Visualization with alkaline phosphatase-conjugated secondary Abs showed that the BORIS- and CTCF-specific signals distribute to different populations of germ-line cells (Fig. 4 A, B, E, and F). The control slides showed only low background signals (Fig. 4 C and D). Whereas CTCF expression was detected in almost exclusively postmeiotic cells (round spermatids), expression of BORIS was restricted to primarily spermatocytes in adjacent sections (Fig. 4 E and F; see also Fig. 4 G and H). On these sections, most of the signal specific for the BORIS peptide-2 epitope appeared in cytoplasm rather than in nuclei (marked by arrowheads in Fig. 4E). Because DNA-binding activity of BORIS was initially detected in testis NE (Fig. 1A), we analyzed BORIS-positive cells for subcellular distribution of BORIS and CTCF by Western blotting of cytoplasmic and nuclear fractions obtained by the PEG-Dextran-Triton-extraction method that preserves natural nuclear-cytoplasmic partitioning patterns of fractionated proteins (described and illustrated in Fig. 8). These analyses indicated that approximately 10-30% of BORIS was present in nucleus with the rest in the cytoplasm. In contrast, CTCF was, as expected (9, 15) and shown for testis cells in Fig. 4F, found only in the nucleus.
|
The same cell-type-specific pattern of BORIS expression as in mouse testes (Fig. 4) was also observed in human testis by in situ RT-PCR and by in situ hybridization with a "no-ZFs" cDNA probe (data not shown). Moreover, compared with mouse testes sections, the presence of nuclear-localized BORIS in spermatocytes was seen somewhat better in human samples (data not shown), perhaps because of a higher affinity of the ap-2-Ab for the region of human BORIS peptide-2 with amino acid sequence that is similar, but not identical, to the mouse sequence (Fig. 2B). Although dual immunostaining for CTCF and BORIS was not possible (because the same pretreatments that were necessary to reveal the BORIS epitope have also resulted in a severe loss of CTCF detection), it is clear that BORIS and CTCF expression patterns overlap very little, perhaps not at all. Moreover, because population of BORIS-positive cells includes primary spermatocytes (shown by the arrows in Fig. 4E), activation of BORIS transcription seems to be tightly linked with the final round of mitosis of the male germ-line cells. Fig. 5 summarizes the results as follows: BORIS is up-regulated in primary spermatocytes to become silenced on activation of CTCF in postmeiotic germ-line cells. Strikingly, this sequential up-regulation of BORIS (in CTCF-negative cells) and of CTCF (in BORIS-negative cells) takes place in association with erasure and re-establishment of methylation marks, respectively, as visualized by the Ab against 5mC (Fig. 4 I-L).
|
| |
Discussion |
|---|
|
|
|---|
The major result of this work is the identification of a previously uncharacterized testis-specific gene that has the potential to reshape our thinking about site-specific epigenetic events in the male germ line. The gene has been named BORIS for Brother of the Regulator of Imprinted Sites. The sibling referred to is CTCF, the 11-ZF protein well known for its many roles in gene regulation (reviewed in ref. 1) including functional "reading" of allele-specific methylation marks (2, 10, 22, 23). BORIS shares an identical 11-ZF DNA-binding domain with CTCF as the basis for familial similarity while being completely divergent at the amino and carboxy termini. This finding alone indicates that nucleoprotein complexes generated by BORIS and CTCF bound to the same DNA sites are likely to have distinct functions. For the ZF-coding regions, we noted remarkable similarity in genomic sequence between BORIS and mammalian but not avian CTCF at each splice site, as well as similar overall arrangement of the ZF-coding exons. We therefore suggest that at some point of mammalian evolution, all of the ZF exons of CTCF were duplicated together with other surrounding regions and transposed to a different chromosome.
As a result of their stunning sameness in the ZF domain, BORIS and CTCF demonstrate currently indistinguishable DNA-binding specificity in vitro. In development, differentiation, and function of normal cells, this sharing of specificity cannot result in sibling rivalry because expression of BORIS is restricted to a select cell population in testis that is the only normal cell type known that does not express CTCF. Because inhibition of CTCF expression in cultured cells leads to apoptosis (S.V., D.I.L., E.P., H.M., H.C.M., and V.V.L., unpublished results), it is reasonable to assume that BORIS is activated to maintain some of the vital CTCF functions in these particular cells. Also, switching to BORIS may allow these cells to perform such specific functions that otherwise are inhibited in the presence of CTCF. With respect to the latter proposition, it is striking that the genome-wide erasure of methylation overlaps extensively with BORIS expression, and that remethylation of DNA in round spermatids is associated with the subsequent silencing of BORIS and reactivation of CTCF expression as depicted in Fig. 5. Thus, BORIS could be associated with demethylases that participate in the erasure of methylation marks.
It is also possible that the BORIS-CTCF switching is intimately linked with initiating (or regional targeting) de novo DNA methylation. In this case, reactivation of CTCF would serve to target de novo methylation to the paternal imprinting marks. Marking of chromatin for de novo DNA-methylation appears to involve histone H3 lysine methylases, such as the Suv39h1 and Suv39h2 (24). Because the expression pattern of testis-specific Suv39h (25) is remarkably similar to the pattern of BORIS-CTCF switching (Fig. 5), it would therefore be of great interest to test whether BORIS and CTCF may interact with the Suv39h histone H3 methyltransferases.
The finding of large amounts of BORIS protein in cytoplasm (Fig. 4), confirmed by Western blot analyses of sub fractionated cells (see Fig. 6), is in stark contrast to the strictly nuclear localization of CTCF. However, significant portion of DNA-binding BORIS is localized in nuclei as shown by EMSA with testes NE (Fig. 1A). Moreover, chromatin immunopurification (ChIP) experiments with cells from adult mouse testes showed that BORIS interacts in vivo with certain CTCF-target DNA sites (L. Liu, C.K., and R.O., unpublished observations). We propose therefore that the nuclear import of BORIS may have a regulatory role not shared with its sibling, CTCF; and that BORIS may be capable of selective in vivo occupation of CTCF sites in the maternally imprinted ICR rather than sites in the paternally imprinted ICRs. This important prediction is now being tested based on our knowledge of CTCF "footprints" within these two classes of ICRs exemplified by the Igf2/H19 (2) and Kcnq1 (ref. 9; G. Fitzpatrick, E.P., C.K., R.O., M. Higgins, and V.V.L., unpublished data) loci.
Finally, we showed here that human BORIS maps to 20q13.2. It has been shown that this chromosomal region is amplified in many cancers and may contain a dominant immortalizing or transforming gene(s) (26, 27). Our ongoing studies demonstrate that BORIS transcripts are abnormally activated in varying proportions of a wide variety of cancers (unpublished data). This defines BORIS as a previously unknown member of the cancer-testis (CT) gene family that comprises genes normally expressed only in testis but abnormally activated in different malignancies (28, 29). A conjunction of DNA-demethylation and CTCF-silencing in BORIS-positive cells that express other CT genes may indicate a common mechanism for transcriptional regulation of BORIS and other CT genes. However, BORIS is a unique member of the CT family because, unlike the others, it has a somatic counterpart with the same DNA-binding domain but with the properties of a tumor suppressor (13, 30, 31). Expression of BORIS in addition to CTCF, observed only in cancer cells, can set the stage for competition at IGF2/H19 ICR, and at some other CTCF target sites (1), resulting in cell growth deregulation (unpublished data). We suggest that BORIS and CTCF may act successively to govern epigenetic states in normal male germ cell development, while their rivalry caused by aberrant activation of BORIS in soma is associated with cancer. Therefore, characterization of mouse and human BORIS genes described here is likely to provide opportunities for understanding molecular mechanics of epigenetic reprogramming, both in normal development and in tumor genesis.
| |
Acknowledgements |
|---|
We thank Mrs. Anita Mattsson, Drs. Vladimir Dobrovitsky, David Lee, Zied Abdullaev, and Helena Malmikumpu for excellent technical assistance with preparing and analyzing human and mouse testis specimens; Mr. Hare Varnon, Mrs. Deborrah Curtis, and Dr. Nancy Wolford for the assistance with preparing this manuscript for publication; and Valentina Lobanenkova for great patience and encouragement during the course of the work presented here. This work was supported in part by National Institutes of Health Grants RO1 CA65145 and R37 CA54358 (to A.P.F.), NS30994 (to W.W.Q.), and HD-10793 (to M.K.), as well as grants from the Swedish Cancer Research Foundation and Swedish Pediatric Cancer Foundation (to R.O. and E.L.), the Association for International Cancer Research (to I.C. and E.M.K.), the UK Breast Cancer Campaign (to F.M.D. and E.M.K.), and the Deutsche Forschungsgemeinschaft (to R.R.).
| |
Abbreviations |
|---|
ZF, zinc finger; ICR, imprinting control region; EMSA, electrophoretic mobility shift assay; Ab, antibodies; RT, reverse transcription; NE, nuclear extracts.
| |
Footnotes |
|---|
j Present address: Transgenomic Inc., 11 Firstfield Road, Suite E, Gaithersburg, MD 20878.
l To whom reprint requests should be addressed at: Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 7, Room 303, 7 Center Drive, MSC 0760, Bethesda, MD 20892. E-mail: vlobanenkov{at}niaid.nih.gov.
Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession no. AF336042).
m Ohta, T., Khadake, J. R., Rodriguez-Jato, S., Mione, C., Knepper, J. L., Svoboda, P., McCarrey, J. R., Schultz, R. M., Yang, T. P. & Nicholls, R. D. (2001) Am. J. Hum. Genet. 69, 52 (abstr.).
| |
References |
|---|
|
|
|---|
| 1. |
Ohlsson, R.
, Renkawitz, R.
& Lobanenkov, V.
(2001)
Trends Genet.
17,
520-527[CrossRef][ISI][Medline]
|
| 2. |
Kanduri, C.
, Pant, V.
, Loukinov, D.
, Pugacheva, E.
, Qi, C. F.
, Wolffe, A.
, Ohlsson, R.
& Lobanenkov, V. V.
(2000)
Curr. Biol.
10,
853-856[CrossRef][ISI][Medline]
|
| 3. |
Filippova, G. N.
, Thienes, C. P.
, Penn, B. H.
, Cho, D. H.
, Hu, Y. J.
, Moore, J. M.
, Klesert, T. R.
, Lobanenkov, V. V.
& Tapscott, S. J.
(2001)
Nat. Genet.
28,
335-343[CrossRef][ISI][Medline]
|
| 4. |
Bell, A. C.
, West, A. G.
& Felsenfeld, G.
(2001)
Science
291,
447-450 |
| 5. |
Holmgren, C.
, Kanduri, C.
, Dell, G.
, Ward, A.
, Mukhopadhya, R.
, Kanduri, M.
, Lobanenkov, V.
& Ohlsson, R.
(2001)
Curr. Biol.
11,
1128-1130[CrossRef][ISI][Medline]
|
| 6. |
West, A. G.
, Gaszner, M.
& Felsenfeld, G.
(2002)
Genes Dev.
16,
271-288 |
| 7. |
Paulsen, M.
, Takada, S.
, Youngson, N. A.
, Benchaib, M.
, Charlier, C.
, Segers, K.
, Georges, M.
& Ferguson-Smith, A. C.
(2001)
Genome Res.
11,
2085-2094 |
| 8. |
Takada, S.
, Paulsen, M.
, Tevendale, M.
, Tsai, C. E.
, Kelsey, G.
, Cattanach, B. M.
& Ferguson-Smith, A. C.
(2002)
Hum. Mol. Genet.
11,
77-86 |
| 9. | Kanduri, C., Fitzpatrick, G., Mukhopadhyay, R., Kanduri, M., Lobanenkov, V., Higgins, M. & Ohlsson, R. (2002) J. Biol. Chem., 10.1074/jbc.M200031200. |
| 10. |
Chao, W.
, Huynh, K. D.
, Spencer, R. J.
, Davidow, L. S.
& Lee, J. T.
(2002)
Science
295,
345-347 |
| 11. |
Lobanenkov, V. V.
, Nicolas, R. H.
, Adler, V. V.
, Paterson, H.
, Klenova, E. M.
, Polotskaja, A. V.
& Goodwin, G. H.
(1990)
Oncogene
5,
1743-1753[ISI][Medline]
|
| 12. |
Vostrov, A. A.
, Taheny, M. J.
& Quitschke, W. W.
(2002)
J. Biol. Chem.
277,
1619-1627 |
| 13. |
Filippova, G. N.
, Qi, C. F.
, Ulmer, J. E.
, Moore, J. M.
, Ward, M. D.
, Hu, Y. J.
, Loukinov, D. I.
, Pugacheva, E. M.
, Klenova, E. M.
, Grundy, P. E.
,
et al.
(2002)
Cancer Res.
62,
48-52 |
| 14. |
Filippova, G. N.
, Fagerlie, S.
, Klenova, E. M.
, Myers, C.
, Dehner, Y.
, Goodwin, G.
, Neiman, P. E.
, Collins, S. J.
& Lobanenkov, V. V.
(1996)
Mol. Cell. Biol.
16,
2802-2813[Abstract] |
| 15. |
Quitschke, W. W.
, Taheny, M. J.
, Fochtmann, L. J.
& Vostrov, A. A.
(2000)
Nucleic Acids Res.
28,
3370-3378 |
| 16. |
Klenova, E. M.
, Nicolas, R. H., U, S.
, Carne, A. F.
, Lee, R. E.
, Lobanenkov, V. V.
& Goodwin, G. H.
(1997)
Nucleic Acids Res.
25,
466-474 |
| 17. |
Klenova, E. M.
, Nicolas, R. H.
, Paterson, H. F.
, Carne, A. F.
, Heath, C. M.
, Goodwin, G. H.
, Neiman, P. E.
& Lobanenkov, V. V.
(1993)
Mol. Cell. Biol.
13,
7612-7624 |
| 18. |
Pack, S. D.
, Zbar, B.
, Pak, E.
, Ault, D. O.
, Humphrey, J. S.
, Pham, T.
, Hurley, K.
, Weil, R. J.
, Park, W. S.
, Kuzmin, I.
,
et al.
(1999)
Cancer Res.
59,
5560-5564 |
| 19. |
Awad, T. A.
, Bigler, J.
, Ulmer, J. E.
, Hu, Y. J.
, Moore, J. M.
, Lutz, M.
, Neiman, P. E.
, Collins, S. J.
, Renkawitz, R.
, Lobanenkov, V. V.
& Filippova, G. N.
(1999)
J. Biol. Chem.
274,
27092-27098 |
| 20. |
Klenova, E. M.
, Fagerlie, S.
, Filippova, G. N.
, Kretzner, L.
, Goodwin, G. H.
, Loring, G.
, Neiman, P. E.
& Lobanenkov, V. V.
(1998)
J. Biol. Chem.
273,
26571-26579 |
| 21. |
Popovici, C.
, Leveugle, M.
, Birnbaum, D.
& Coulier, F.
(2001)
Biochem. Biophys. Res. Commun.
288,
362-370[CrossRef][ISI][Medline]
|
| 22. |
Bell, A. C.
& Felsenfeld, G.
(2000)
Nature (London)
405,
482-485[CrossRef][Medline]
|
| 23. |
Hark, A. T.
, Schoenherr, C. J.
, Katz, D. J.
, Ingram, R. S.
, Levorse, J. M.
& Tilghman, S. M.
(2000)
Nature (London)
405,
486-489[CrossRef][Medline]
|
| 24. |
Bird, A.
(2002)
Genes Dev.
16,
6-21 |
| 25. |
O'Carroll, D.
, Scherthan, H.
, Peters, A. H.
, Opravil, S.
, Haynes, A. R.
, Laible, G.
, Rea, S.
, Schmid, M.
, Lebersorger, A.
, Jerratsch, M.
,
et al.
(2000)
Mol. Cell. Biol.
20,
9423-9433 |
| 26. |
Tanner, M. M.
, Tirkkonen, M.
, Kallioniemi, A.
, Collins, C.
, Stokke, T.
, Karhu, R.
, Kowbel, D.
, Shadravan, F.
, Hintz, M.
, Kuo, W. L.
,
et al.
(1994)
Cancer Res.
54,
4257-4260 |
| 27. |
Cuthill, S.
, Agarwal, P.
, Sarkar, S.
, Savelieva, E.
& Reznikoff, C. A.
(1999)
Genes Chromosomes Cancer
26,
304-311[CrossRef][ISI][Medline]
|
| 28. |
Chen, Y. T.
, Gure, A. O.
, Tsang, S.
, Stockert, E.
, Jager, E.
, Knuth, A.
& Old, L. J.
(1998)
Proc. Natl. Acad. Sci. USA
95,
6919-6923 |
| 29. |
Renkvist, N.
, Castelli, C.
, Robbins, P. F.
& Parmiani, G.
(2001)
Cancer Immunol. Immunother.
50,
3-15[CrossRef][ISI][Medline]
|
| 30. |
Filippova, G. N.
, Lindblom, A.
, Meincke, L. J.
, Klenova, E. M.
, Neiman, P. E.
, Collins, S. J.
, Doggett, N. A.
& Lobanenkov, V. V.
(1998)
Genes Chromosomes Cancer
22,
26-36[CrossRef][ISI][Medline]
|
| 31. |
Rasko, J. E.
, Klenova, E. M.
, Leon, J.
, Filippova, G. N.
, Loukinov, D. I.
, Vatolin, S.
, Robinson, A. F.
, Hu, Y. J.
, Ulmer, J.
, Ward, M. D.
,
et al.
(2001)
Cancer Res.
61,
6002-6007 |
| 32. |
Aravind, L.
& Landsman, D.
(1998)
Nucleic Acids Res.
26,
4413-4421 |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
L. Sun, L. Huang, P. Nguyen, K. S. Bisht, G. Bar-Sela, A. S. Ho, C. M. Bradbury, W. Yu, H. Cui, S. Lee, et al. DNA Methyltransferase 1 and 3B Activate BAG-1 Expression via Recruitment of CTCFL/BORIS and Modulation of Promoter Histone Methylation Cancer Res., April 15, 2008; 68(8): 2726 - 2735. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Renaud, E. M. Pugacheva, M. D. Delgado, R. Braunschweig, Z. Abdullaev, D. Loukinov, J. Benhattar, and V. Lobanenkov Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors Nucleic Acids Res., December 18, 2007; 35(21): 7372 - 7388. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Biermann and K. Steger Epigenetics in Male Germ Cells J Androl, July 1, 2007; 28(4): 466 - 480. [Full Text] [PDF] |
||||
![]() |
J. D. Kim, C. Faulk, and J. Kim Retroposition and evolution of the DNA-binding motifs of YY1, YY2 and REX1 Nucleic Acids Res., May 11, 2007; 35(10): 3442 - 3452. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rathke, W. M. Baarends, S. Jayaramaiah-Raja, M. Bartkuhn, R. Renkawitz, and R. Renkawitz-Pohl Transition from a nucleosome-based to a protamine-based chromatin configuration during spermiogenesis in Drosophila J. Cell Sci., May 1, 2007; 120(9): 1689 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Price, S. K. Murphy, and E. V. Younglai Perspectives: The Possible Influence of Assisted Reproductive Technologies on Transgenerational Reproductive Effects of Environmental Endocrine Disruptors Toxicol. Sci., April 1, 2007; 96(2): 218 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Risinger, G. V.R. Chandramouli, G. L. Maxwell, M. Custer, S. Pack, D. Loukinov, O. Aprelikova, T. Litzi, D. S. Schrump, S. K. Murphy, et al. Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression Clin. Cancer Res., March 15, 2007; 13(6): 1713 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Renaud, D. Loukinov, Z. Abdullaev, I. Guilleret, F. T. Bosman, V. Lobanenkov, and J. Benhattar Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene Nucleic Acids Res., February 28, 2007; 35(4): 1245 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Hancock, K. W. Brown, K. Moorwood, H. Moon, C. Holmgren, S. H. Mardikar, A. R. Dallosso, E. Klenova, D. Loukinov, R. Ohlsson, et al. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis Hum. Mol. Genet., February 1, 2007; 16(3): 343 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ghochikyan, M. Mkrtichyan, D. Loukinov, G. Mamikonyan, S. D. Pack, N. Movsesyan, T. E. Ichim, D. H. Cribbs, V. V. Lobanenkov, and M. G. Agadjanyan Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites J. Immunol., January 1, 2007; 178(1): 566 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kim, D. Li, Y. Cui, K. Mueller, W. C. Chears, and J. DeJong Regulatory Factor Interactions and Somatic Silencing of the Germ Cell-specific ALF Gene J. Biol. Chem., November 10, 2006; 281(45): 34288 - 34298. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. D'Arcy, Z. K. Abdullaev, N. Pore, F. Docquier, V. Torrano, I. Chernukhin, M. Smart, D. Farrar, M. Metodiev, N. Fernandez, et al. The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis. Clin. Cancer Res., October 15, 2006; 12(20): 5978 - 5986. [Abstract] [Full Text] [PDF] |
||||